NAD+ Myths: 7 Claims Checked Against the Evidence

Most NAD+ myths start with a true fact and stretch it too far. NAD+ is nicotinamide adenine dinucleotide, a helper molecule cells use to handle energy and repair. Some oral supplements raise its level in blood. Neither fact establishes that an injection makes people younger, improves energy, or works better than other formats.

A higher lab number can be real without the hoped-for benefit being real. The useful questions are what was given, how it was given, and what changed for people.

NAD+ myths: what each verdict means

Supported means the evidence backs the claim as stated. Partly means one piece holds up. Not supported means the claim outruns the evidence. Unknown means the question hasn't been answered well enough.

1. "NAD+ makes people younger."

Not supported. Human evidence hasn't established NAD+ injections as a way to make people younger. NAD+'s role in cell repair explains the interest; it doesn't establish a treatment outcome. NR, or nicotinamide riboside, is a precursor: an ingredient the body uses to make NAD+.

The NOPARK trial in Parkinson's disease found no symptom benefit from nicotinamide riboside, despite increased blood NAD metabolism.

As of September 30, 2026, the day this article was written, a trial published July 21, 2026 offers a useful reality check. Among 42 older adults with memory problems who completed 12 weeks, oral NR roughly doubled blood NAD+. Memory and thinking did not significantly improve compared with capsules containing no NR (Martens and colleagues, Alzheimer's & Dementia, 2026). That tests oral NR in a specific group, rather than an anti-aging injection.

2. "NAD+ falls in everyone as they get older."

Partly. A 2012 study found lower NAD+ with age in skin samples from 49 people (Massudi and colleagues, PLOS ONE, 2012). It compared different people at different ages; it didn't follow one person across decades. A skin finding doesn't describe every tissue or establish a universal percentage decline.

As of September 30, 2026, the day this article was written, newer human evidence challenges the blanket claim. A study published May 14, 2026 found blood NAD+ stayed stable with age across seven separate groups of people (Trętowicz and colleagues, Nature Metabolism, 2026). Blood and skin aren't interchangeable measurements. A blood NAD+ result alone isn't an established measure of how someone is aging.

3. "An NAD+ IV works better than a shot."

Unknown. IV means delivery straight into a vein. In a 2019 pilot, eight men received NAD+ over six hours while researchers tracked blood and urine breakdown products (Grant and colleagues, Frontiers in Aging Neuroscience, 2019). It wasn't a test of whether people felt better or a comparison with shots under the skin.

As of September 30, 2026, the day this article was written, a paper published February 2, 2026 also documents IV discomfort. All six NAD+ IV clients reported symptoms including nausea and chest pressure during infusions (Reyna and colleagues, Frontiers in Aging, 2026). That review of clinic records compared NAD+ with NR infusions, rather than NAD+ shots. The NAD+ IV death report explains why placing and monitoring an IV line matters separately from the molecule.

4. "Oral NR and NMN can raise blood NAD+."

Supported for blood measurements. Conze and colleagues' eight-week trial enrolled 140 adults with overweight who were otherwise healthy. Three oral NR doses raised blood NAD+ by 22%, 51%, and 142% after two weeks; the increases were maintained through eight weeks (Scientific Reports, 2019). Those are study results, rather than amounts to copy.

NMN, or nicotinamide mononucleotide, is another ingredient the body uses to make NAD+. As of September 30, 2026, the day this article was written, a trial published September 25, 2026 adds longer follow-up. It assigned 62 adults aged 65 or older to NMN or comparison capsules for 24 weeks. Blood NAD+ rose with NMN, but hearing and physical performance did not significantly improve (Igarashi and colleagues, npj Aging, 2026).

These findings support a blood measurement. They don't establish that NAD+ injections produce the same result or a health benefit.

5. "If it's safe in a supplement, it's safe to inject."

Not supported. An ingredient suitable for food isn't automatically suitable for injection. In its October 30, 2024 NAD+ compounding notice, FDA described food-grade ingredients used for IV products. It reported severe chills, shaking, vomiting and fatigue consistent with excessive endotoxin: bacterial residue that can trigger fever and shaking. The NAD+ injection side-effects guide covers both infusion discomfort and possible contamination.

As of September 30, 2026, the day this article was written, a later enforcement file includes both findings and follow-up. A February 9, 2026 FDA letter raised concerns about NAD+ repackaging and how injectable products were kept free of germs. Its July 27, 2026 close-out letter said the firm appeared to have addressed the violations. The distinction between a food ingredient and an injectable preparation still matters.

6. "A prescription means the FDA reviewed the injection."

Not supported. A compounded medication is prepared by a pharmacy for a prescription. Promise offers NAD+ by prescription, after a licensed provider reviews your request. It is dispensed as a compounded injectable medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved.

FDA does not verify compounded drugs' safety, effectiveness or quality before marketing, as its compounding explanation states. A prescription provides a clinical relationship; it doesn't change that review status. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.

7. "A bigger NAD+ dose gives bigger benefits."

Unknown. Larger oral NR doses raised blood numbers more in the Conze trial, but that doesn't establish a better NAD+ injection dose. The trial did not test injected NAD+, aging outcomes, or a maintenance schedule. Capsule milligrams can't be converted into an injection dose from those results. The NAD+ injection guide covers the broader evidence behind the treatment discussion.

Promise's NAD+ page lists only a compounded injectable: a 100 mg/mL × 10 mL vial (1,000 mg). Results from NR or NMN capsules don't automatically apply to this injectable. The prescriber sets the format, dose and schedule for the person.

The evidence does not establish NAD+ timing around workouts; the prescription and pharmacy instructions control.

What a provider can put behind a claim

A useful visit covers the goal, the uncertain evidence, the formulation, and who handles unwanted effects. For any prescribed preparation, the pharmacy's identity, the labeled ingredients and the lot number are concrete questions. A route without a prescription leaves out that clinical review; a prescription adds it without making thin evidence stronger.

The September NAD+ update covers the dated research and regulatory changes. At Promise, a licensed provider reviews every request, and not everyone qualifies.